Company news
Clinuvel Pharmaceuticals Limited (ASX:CUV) news
Every Clinuvel Pharmaceuticals Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
August 27, 2026
CLINUVEL considers Nasdaq listing, ASX delisting
August 26, 2026
Commercial update on vitiligo
July 29, 2026
Update - SCENESSE in vitiligo
July 27, 2026
CLINUVEL implements strategic reorganisation to refocus on U.S. markets
July 23, 2026
CLINUVEL strategic reorganisation to refocus on U.S. markets
July 22, 2026
SCENESSE® approved for EPP in Canada
July 13, 2026
SCENESSE approved for EPP in Canada
July 12, 2026
CLINUVEL publicly files 20-F to U.S. SEC
June 15, 2026
CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
April 27, 2026
FDA relaxes SCENESSE postmarketing requirement
April 26, 2026
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
April 24, 2026
Final EMA scientific advice for pivotal Phase III vitiligo
April 23, 2026
CLINUVEL's global programs showcased at AAD
March 26, 2026
Chair Letter to Shareholders
March 19, 2026
Half Year Results Presentation
February 25, 2026
CLINUVEL Record Revenues, Advances Strategic Expansion
February 25, 2026
Appendix 4D and Half Year Report
February 25, 2026
CLINUVEL - injectable peptide platform in preclinical study
January 11, 2026
CLINUVEL expands Singapore RD&I Centre
December 7, 2025
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
December 6, 2025
CLINUVEL advances new formulations in preclinical program
September 28, 2025
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
September 27, 2025
EMA approves year-round SCENESSE treatment
September 22, 2025
SCENESSE efficacy in vitiligo - new cases presented to EADV
September 18, 2025
Investor Presentation
August 27, 2025
CLINUVEL delivers ninth consecutive revenues growth & profit
August 27, 2025
Appendix 4E and Annual Report to Shareholders 2025
August 27, 2025
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
August 22, 2025
CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
August 21, 2025
Study confirms NB-UVB needed to activate repigmentation
June 17, 2025
CLINUVEL management update
June 12, 2025
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
May 7, 2025
CUV recruits 200 patients in Phase III vitiligo trial CUV105
May 6, 2025
CLINUVEL renews share buy-back program
March 26, 2025
Positive preliminary results for PRENUMBRA Instant in stroke
March 25, 2025
Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025
March 2, 2025
Half Year Results Announcement
February 27, 2025
Preliminary results from SCENESSE adolescent EPP study
February 9, 2025
Vitiligo - CUV105 Study Update
January 19, 2025
Health Canada validates SCENESSE New Drug Submission
December 22, 2024
Chair's letter to Shareholders
December 4, 2024
SCENESSE dosage expansion under review by EMA
November 19, 2024
CLINUVEL prioritises three strategic programs
November 17, 2024
Managing Director Presentation
October 15, 2024
Canadian New Drug Submission for SCENESSE in EPP filed
September 30, 2024
CLINUVEL delivers increases in annual revenue, profit
August 28, 2024
Appendix 4E and Annual Report to Shareholders 2024
August 28, 2024
Vitiligo and Operational Update
August 20, 2024
Afamelanotide Assists DNA Repair Response Following UVR
July 5, 2024